{
  "run": {
    "id": "cmnr14gz104tqp6588uvwhpkl",
    "region": "US",
    "assetId": "cmnr14gxk04tmp658sdpp2tsc",
    "ticker": "LLY",
    "snapshotId": "cmnr14gy704top65825rjqtvt",
    "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux",
    "createdAt": "2026-04-09T05:21:18.826Z",
    "promptTemplate": {
      "id": "cmnqt07si0005lm3jzpxuu1ux",
      "name": "Oficial 08.apr.2026",
      "version": 1
    },
    "snapshot": {
      "id": "cmnr14gy704top65825rjqtvt",
      "assetId": "cmnr14gxk04tmp658sdpp2tsc",
      "asOf": "2026-04-08T20:03:03.000Z",
      "snapshot": {
        "asOf": "2026-04-08T20:03:03.000Z",
        "quote": {
          "asOf": "2026-04-08T20:03:03.000Z",
          "open": null,
          "price": 953.3,
          "dayLow": 933.13,
          "volume": 2566527,
          "dayHigh": 961.135,
          "currency": "USD",
          "prevClose": 931.09,
          "week52Low": 623.78,
          "week52High": 1133.95
        },
        "fundamentals": {
          "pe": 46.7252173913043,
          "beta": 0.582198955534887,
          "epsTTM": 23,
          "fcfTTM": 7243400000,
          "growth": {
            "epsYoy": 0.9557823129251701,
            "revenueYoy": 0.4470491333778837
          },
          "sector": "Pharmaceutical Preparations",
          "margins": {
            "net": 0.3166664109605855,
            "gross": null,
            "operating": null
          },
          "website": "https://www.lilly.com/",
          "industry": "Pharmaceutical",
          "pegRatio": 0.488868822528238,
          "ebitdaTTM": 34346000000,
          "forwardPe": 31.0332082009818,
          "marketCap": 807887000000,
          "totalCash": 7268000000,
          "totalDebt": 42503000000,
          "debtEquity": 1.60177124552478,
          "quickRatio": 0.7109117747246508,
          "revenueTTM": 65179000000,
          "companyName": "ELI LILLY & Co",
          "priceToBook": 36.3410726964387,
          "currentRatio": 1.579113205404792,
          "dividendYield": 0.00558326468427337,
          "returnOnAssets": 0.1835058145737757,
          "returnOnEquity": 0.77784058790277,
          "analystOpinions": null,
          "businessSummary": "Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.",
          "enterpriseValue": 999545364000,
          "analystTargetLow": null,
          "analystTargetHigh": null,
          "analystTargetMean": null,
          "fullTimeEmployees": 50000,
          "sharesOutstanding": 943357420,
          "enterpriseToEbitda": 29.10223502008968,
          "analystTargetMedian": null,
          "enterpriseToRevenue": 15.33538968072539,
          "operatingCashflowTTM": 16813000000,
          "analystRecommendationKey": null
        }
      },
      "createdAt": "2026-04-09T05:21:18.800Z"
    },
    "results": [
      {
        "id": "cmnr14gz404tsp6584yd6k0am",
        "runId": "cmnr14gz104tqp6588uvwhpkl",
        "modelId": "anthropic",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:03:03.000Z\",\"ticker\":\"LLY\",\"currency\":\"USD\",\"current_price\":953.3,\"target_price_6m\":1025,\"target_price_12m\":1075,\"recommendation\":\"BUY\",\"confidence\":0.64,\"thesis_bullets\":[\"GLP-1 franchise (Mounjaro/Zepbound) drives exceptional revenue growth near 45% YoY\",\"Forward P/E of 31x with PEG ~0.49 suggests growth not fully priced in\",\"Pipeline depth with oral GLP-1 orforglipron and retatrutide offer incremental catalysts\",\"Manufacturing capacity buildout supports multi-year supply ramp for obesity market\",\"Competitive threats from Novo Nordisk and emerging oral GLP-1s cap valuation re-rating\"],\"key_drivers\":[{\"driver\":\"Mounjaro/Zepbound volume growth and market share gains\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Obesity market TAM expansion globally\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Orforglipron oral GLP-1 regulatory progress\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Retatrutide triple-agonist clinical data\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Manufacturing capacity expansion execution\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Novo Nordisk CagriSema and competitive launches\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"US drug pricing reform / IRA negotiation risk\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Elevated debt levels from capex buildout\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Patent cliff beyond 2030 on core molecules\",\"impact\":\"LOW\",\"direction\":\"NEG\"},{\"driver\":\"Low beta (0.58) provides defensive quality in risk-off markets\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Competition from Novo Nordisk semaglutide and emerging GLP-1 therapies could erode market share\",\"US drug pricing legislation or IRA negotiations may compress margins on Mounjaro\",\"Manufacturing scale-up delays could constrain supply and revenue realization\",\"Unexpected safety signals for GLP-1 class drugs could impair demand trajectory\",\"Premium valuation leaves stock vulnerable to any earnings miss or guidance cut\"],\"assumptions\":{\"revenue_cagr_3y\":0.22,\"ebit_margin_target\":0.38,\"wacc\":0.085,\"terminal_multiple\":28},\"scenarios\":{\"bear\":{\"target_price\":780,\"prob\":0.2,\"notes\":\"GLP-1 competition intensifies sharply, growth decelerates to mid-teens, multiple compresses to 25x fwd.\"},\"base\":{\"target_price\":1075,\"prob\":0.55,\"notes\":\"Continued strong GLP-1 execution with ~25% revenue growth, forward PE sustains ~30x on ~$36 EPS.\"},\"bull\":{\"target_price\":1320,\"prob\":0.25,\"notes\":\"Pipeline catalysts drive re-rating, obesity market exceeds expectations, forward PE expands to 33x.\"}},\"method_notes\":\"Valuation anchored on forward earnings power (~$35-36 FY+1 EPS) at 30x fwd P/E, cross-checked with EV/EBITDA (28x terminal). PEG of 0.49 supports growth-adjusted attractiveness. 12M base target of $1,075 implies ~13% upside, consistent with BUY. High valuation and competitive risks temper confidence to 0.64. Sell-side consensus noted but not used as numeric input. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:03:03.000Z",
          "model": "ai-equity-research-v1",
          "risks": [
            "Competition from Novo Nordisk semaglutide and emerging GLP-1 therapies could erode market share",
            "US drug pricing legislation or IRA negotiations may compress margins on Mounjaro",
            "Manufacturing scale-up delays could constrain supply and revenue realization",
            "Unexpected safety signals for GLP-1 class drugs could impair demand trajectory",
            "Premium valuation leaves stock vulnerable to any earnings miss or guidance cut"
          ],
          "ticker": "LLY",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.55,
              "notes": "Continued strong GLP-1 execution with ~25% revenue growth, forward PE sustains ~30x on ~$36 EPS.",
              "target_price": 1075
            },
            "bear": {
              "prob": 0.2,
              "notes": "GLP-1 competition intensifies sharply, growth decelerates to mid-teens, multiple compresses to 25x fwd.",
              "target_price": 780
            },
            "bull": {
              "prob": 0.25,
              "notes": "Pipeline catalysts drive re-rating, obesity market exceeds expectations, forward PE expands to 33x.",
              "target_price": 1320
            }
          },
          "confidence": 0.64,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.22,
            "terminal_multiple": 28,
            "ebit_margin_target": 0.38
          },
          "key_drivers": [
            {
              "driver": "Mounjaro/Zepbound volume growth and market share gains",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Obesity market TAM expansion globally",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Orforglipron oral GLP-1 regulatory progress",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Retatrutide triple-agonist clinical data",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Manufacturing capacity expansion execution",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Novo Nordisk CagriSema and competitive launches",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "US drug pricing reform / IRA negotiation risk",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Elevated debt levels from capex buildout",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Patent cliff beyond 2030 on core molecules",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "Low beta (0.58) provides defensive quality in risk-off markets",
              "impact": "LOW",
              "direction": "POS"
            }
          ],
          "method_notes": "Valuation anchored on forward earnings power (~$35-36 FY+1 EPS) at 30x fwd P/E, cross-checked with EV/EBITDA (28x terminal). PEG of 0.49 supports growth-adjusted attractiveness. 12M base target of $1,075 implies ~13% upside, consistent with BUY. High valuation and competitive risks temper confidence to 0.64. Sell-side consensus noted but not used as numeric input. Not investment advice.",
          "current_price": 953.3,
          "recommendation": "BUY",
          "thesis_bullets": [
            "GLP-1 franchise (Mounjaro/Zepbound) drives exceptional revenue growth near 45% YoY",
            "Forward P/E of 31x with PEG ~0.49 suggests growth not fully priced in",
            "Pipeline depth with oral GLP-1 orforglipron and retatrutide offer incremental catalysts",
            "Manufacturing capacity buildout supports multi-year supply ramp for obesity market",
            "Competitive threats from Novo Nordisk and emerging oral GLP-1s cap valuation re-rating"
          ],
          "target_price_6m": 1025,
          "target_price_12m": 1075
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "anthropic",
            "webSearch": {
              "enabled": false,
              "maxToolCalls": 2,
              "disabledReason": null
            },
            "pauseTurns": 0,
            "stopReason": "end_turn"
          },
          "sanityIssues": []
        },
        "latencyMs": 34082,
        "createdAt": "2026-04-09T05:21:18.826Z",
        "usage": {
          "inputTokens": 3591,
          "outputTokens": 1723,
          "costUsd": 0.06103
        }
      },
      {
        "id": "cmnr14gz404tvp658rnvxm01w",
        "runId": "cmnr14gz104tqp6588uvwhpkl",
        "modelId": "deepseek.reasoner",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"Pharma DCF Valuation Model\",\n  \"as_of\": \"2026-04-08T20:03:03.000Z\",\n  \"ticker\": \"LLY\",\n  \"currency\": \"USD\",\n  \"current_price\": 953.3,\n  \"target_price_6m\": 1000,\n  \"target_price_12m\": 1050,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.65,\n  \"thesis_bullets\": [\n    \"Strong revenue growth from GLP-1 agonists.\",\n    \"Expanding margins due to product mix.\",\n    \"Robust pipeline with blockbuster potential.\",\n    \"Favorable demographics in obesity markets.\",\n    \"Solid financials with high profitability.\"\n  ],\n  \"key_drivers\": [\n    { \"driver\": \"GLP-1 drug sales growth\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n    { \"driver\": \"Pipeline advancements in neurology\", \"impact\": \"MED\", \"direction\": \"POS\" },\n    { \"driver\": \"International market expansion\", \"impact\": \"MED\", \"direction\": \"POS\" },\n    { \"driver\": \"Cost efficiency improvements\", \"impact\": \"LOW\", \"direction\": \"POS\" },\n    { \"driver\": \"Regulatory approvals for new drugs\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n    { \"driver\": \"Competitive pressure in diabetes drugs\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n    { \"driver\": \"Patent expirations on key products\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n    { \"driver\": \"Currency exchange rate fluctuations\", \"impact\": \"LOW\", \"direction\": \"NEG\" }\n  ],\n  \"risks\": [\n    \"Clinical trial failures for pipeline drugs.\",\n    \"Increased competition in GLP-1 market.\",\n    \"Adverse regulatory changes.\",\n    \"Macroeconomic factors affecting healthcare spending.\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.15,\n    \"ebit_margin_target\": 0.32,\n    \"wacc\": 0.08,\n    \"terminal_multiple\": 28\n  },\n  \"scenarios\": {\n    \"bear\": { \"target_price\": 850, \"prob\": 0.2, \"notes\": \"Weak sales growth and pipeline setbacks.\" },\n    \"base\": { \"target_price\": 1050, \"prob\": 0.6, \"notes\": \"Moderate growth with successful launches.\" },\n    \"bull\": { \"target_price\": 1200, \"prob\": 0.2, \"notes\": \"Strong outperformance and market expansion.\" }\n  },\n  \"method_notes\": \"DCF model with assumed growth and margins; base case implies ~10% upside. Note: snapshot marketCap/price inconsistency, but using snapshot values. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:03:03.000Z",
          "model": "Pharma DCF Valuation Model",
          "risks": [
            "Clinical trial failures for pipeline drugs.",
            "Increased competition in GLP-1 market.",
            "Adverse regulatory changes.",
            "Macroeconomic factors affecting healthcare spending."
          ],
          "ticker": "LLY",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Moderate growth with successful launches.",
              "target_price": 1050
            },
            "bear": {
              "prob": 0.2,
              "notes": "Weak sales growth and pipeline setbacks.",
              "target_price": 850
            },
            "bull": {
              "prob": 0.2,
              "notes": "Strong outperformance and market expansion.",
              "target_price": 1200
            }
          },
          "confidence": 0.65,
          "assumptions": {
            "wacc": 0.08,
            "revenue_cagr_3y": 0.15,
            "terminal_multiple": 28,
            "ebit_margin_target": 0.32
          },
          "key_drivers": [
            {
              "driver": "GLP-1 drug sales growth",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Pipeline advancements in neurology",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "International market expansion",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Cost efficiency improvements",
              "impact": "LOW",
              "direction": "POS"
            },
            {
              "driver": "Regulatory approvals for new drugs",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Competitive pressure in diabetes drugs",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Patent expirations on key products",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Currency exchange rate fluctuations",
              "impact": "LOW",
              "direction": "NEG"
            }
          ],
          "method_notes": "DCF model with assumed growth and margins; base case implies ~10% upside. Note: snapshot marketCap/price inconsistency, but using snapshot values. Not investment advice.",
          "current_price": 953.3,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Strong revenue growth from GLP-1 agonists.",
            "Expanding margins due to product mix.",
            "Robust pipeline with blockbuster potential.",
            "Favorable demographics in obesity markets.",
            "Solid financials with high profitability."
          ],
          "target_price_6m": 1000,
          "target_price_12m": 1050
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "endpoint": "https://api.deepseek.com/v1/chat/completions",
            "provider": "deepseek",
            "webSearch": {
              "enabled": false,
              "supported": false
            },
            "responseFormat": "json_object"
          },
          "sanityIssues": []
        },
        "latencyMs": 369,
        "createdAt": "2026-04-09T05:21:18.826Z",
        "usage": {
          "inputTokens": 2096,
          "outputTokens": 3988,
          "costUsd": 0.002262
        }
      },
      {
        "id": "cmnr14gz404ttp6583ueai2rn",
        "runId": "cmnr14gz104tqp6588uvwhpkl",
        "modelId": "gemini.3-pro",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"Equity Research AI\",\"as_of\":\"2026-04-08T20:03:03.000Z\",\"ticker\":\"LLY\",\"currency\":\"USD\",\"current_price\":953.3,\"target_price_6m\":1030.0,\"target_price_12m\":1120.0,\"recommendation\":\"BUY\",\"confidence\":0.72,\"thesis_bullets\":[\"Dominant position in the rapidly expanding GLP-1 market for obesity and diabetes.\",\"Significant margin expansion potential as manufacturing scales and high-margin products ramp.\",\"Robust R&D pipeline including oral GLP-1 and promising Alzheimer’s treatments.\",\"Exceptional revenue and EPS growth rates far exceeding large-cap pharmaceutical peers.\",\"Valuation supported by high growth visibility despite premium absolute P/E multiples.\"],\"key_drivers\":[{\"driver\":\"Zepbound and Mounjaro prescription volume growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Manufacturing capacity expansion and facility scaling\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Clinical trial results for oral GLP-1 orforglipron\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Market penetration of Donanemab in Alzheimer's disease\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Medicare drug price negotiation and regulatory pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Competitive product launches from Novo Nordisk and others\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"International market expansion and reimbursement approvals\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Regulatory pricing pressure and Medicare negotiation impacts in the US.\",\"Supply chain bottlenecks limiting product availability and revenue potential.\",\"Emergence of long-term safety concerns for GLP-1 receptor agonists.\",\"Intensifying competition in the weight-loss and diabetes categories.\"],\"assumptions\":{\"revenue_cagr_3y\":0.32,\"ebit_margin_target\":0.42,\"wacc\":0.075,\"terminal_multiple\":25.0},\"scenarios\":{\"bear\":{\"target_price\":850.0,\"prob\":0.25,\"notes\":\"Severe pricing caps and safety setbacks for GLP-1 class.\"},\"base\":{\"target_price\":1120.0,\"prob\":0.5,\"notes\":\"Steady GLP-1 growth and successful manufacturing capacity expansion.\"},\"bull\":{\"target_price\":1300.0,\"prob\":0.25,\"notes\":\"Oral GLP-1 breakthrough and faster-than-expected production scaling.\"}},\"method_notes\":\"Valuation uses a 32x forward P/E multiple on projected 2027 earnings. Upside driven by GLP-1 dominance and pipeline execution. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:03:03.000Z",
          "model": "Equity Research AI",
          "risks": [
            "Regulatory pricing pressure and Medicare negotiation impacts in the US.",
            "Supply chain bottlenecks limiting product availability and revenue potential.",
            "Emergence of long-term safety concerns for GLP-1 receptor agonists.",
            "Intensifying competition in the weight-loss and diabetes categories."
          ],
          "ticker": "LLY",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Steady GLP-1 growth and successful manufacturing capacity expansion.",
              "target_price": 1120
            },
            "bear": {
              "prob": 0.25,
              "notes": "Severe pricing caps and safety setbacks for GLP-1 class.",
              "target_price": 850
            },
            "bull": {
              "prob": 0.25,
              "notes": "Oral GLP-1 breakthrough and faster-than-expected production scaling.",
              "target_price": 1300
            }
          },
          "confidence": 0.72,
          "assumptions": {
            "wacc": 0.075,
            "revenue_cagr_3y": 0.32,
            "terminal_multiple": 25,
            "ebit_margin_target": 0.42
          },
          "key_drivers": [
            {
              "driver": "Zepbound and Mounjaro prescription volume growth",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Manufacturing capacity expansion and facility scaling",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Clinical trial results for oral GLP-1 orforglipron",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Market penetration of Donanemab in Alzheimer's disease",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Medicare drug price negotiation and regulatory pressure",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Competitive product launches from Novo Nordisk and others",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "International market expansion and reimbursement approvals",
              "impact": "MED",
              "direction": "POS"
            }
          ],
          "method_notes": "Valuation uses a 32x forward P/E multiple on projected 2027 earnings. Upside driven by GLP-1 dominance and pipeline execution. Not investment advice.",
          "current_price": 953.3,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Dominant position in the rapidly expanding GLP-1 market for obesity and diabetes.",
            "Significant margin expansion potential as manufacturing scales and high-margin products ramp.",
            "Robust R&D pipeline including oral GLP-1 and promising Alzheimer’s treatments.",
            "Exceptional revenue and EPS growth rates far exceeding large-cap pharmaceutical peers.",
            "Valuation supported by high growth visibility despite premium absolute P/E multiples."
          ],
          "target_price_6m": 1030,
          "target_price_12m": 1120
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "model": "gemini-3-flash-preview",
            "provider": "gemini",
            "webSearch": {
              "used": false,
              "allowed": false,
              "enabled": false,
              "requested": false,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 18275,
        "createdAt": "2026-04-09T05:21:18.826Z",
        "usage": {
          "inputTokens": 2443,
          "outputTokens": 587,
          "costUsd": 0.01193
        }
      },
      {
        "id": "cmnr14gz404trp658n1ca9pym",
        "runId": "cmnr14gz104tqp6588uvwhpkl",
        "modelId": "openai.gpt-5.4",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:03:03.000Z\",\"ticker\":\"LLY\",\"currency\":\"USD\",\"current_price\":953.3,\"target_price_6m\":1008,\"target_price_12m\":990,\"recommendation\":\"HOLD\",\"confidence\":0.65,\"thesis_bullets\":[\"Obesity franchise still drives outsized revenue and EPS growth.\",\"Forward P/E near 31x already discounts substantial execution success.\",\"Supply additions support volumes, but pricing pressure may intensify.\",\"Pipeline optionality, especially oral incretins, underpins premium valuation.\",\"Risk-reward looks balanced after sharp rerating; limited 12M upside.\"],\"key_drivers\":[{\"driver\":\"Zepbound/Mounjaro demand growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Manufacturing capacity expansion\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Obesity net pricing pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Oral incretin pipeline readouts\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"International obesity launches\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Policy and reimbursement scrutiny\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Gross-to-net mix shift\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Core portfolio durability\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"GLP-1 supply ramp delays\",\"Medicare or PBM pricing pressure\",\"Obesity safety or litigation issues\",\"Pipeline setbacks in oral incretins\",\"Rich valuation compresses on slower growth\"],\"assumptions\":{\"revenue_cagr_3y\":0.23,\"ebit_margin_target\":0.42,\"wacc\":0.08,\"terminal_multiple\":26},\"scenarios\":{\"bear\":{\"target_price\":760,\"prob\":0.25,\"notes\":\"Growth slows and multiples compress on pricing or supply concerns.\"},\"base\":{\"target_price\":990,\"prob\":0.5,\"notes\":\"Strong obesity growth continues, but premium valuation limits upside.\"},\"bull\":{\"target_price\":1220,\"prob\":0.25,\"notes\":\"Supply, launches, and pipeline catalysts exceed already high expectations.\"}},\"method_notes\":\"Weighted scenario valuation anchored to snapshot fundamentals, forward-growth expectations, and premium pharma multiple discipline; no sell-side price targets used. Snapshot quote fields were kept authoritative. HOLD fits ~4% 12M upside versus current price with meaningful policy, supply, and valuation risk; not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:03:03.000Z",
          "model": "AI Model Recommendation v2",
          "risks": [
            "GLP-1 supply ramp delays",
            "Medicare or PBM pricing pressure",
            "Obesity safety or litigation issues",
            "Pipeline setbacks in oral incretins",
            "Rich valuation compresses on slower growth"
          ],
          "ticker": "LLY",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Strong obesity growth continues, but premium valuation limits upside.",
              "target_price": 990
            },
            "bear": {
              "prob": 0.25,
              "notes": "Growth slows and multiples compress on pricing or supply concerns.",
              "target_price": 760
            },
            "bull": {
              "prob": 0.25,
              "notes": "Supply, launches, and pipeline catalysts exceed already high expectations.",
              "target_price": 1220
            }
          },
          "confidence": 0.65,
          "assumptions": {
            "wacc": 0.08,
            "revenue_cagr_3y": 0.23,
            "terminal_multiple": 26,
            "ebit_margin_target": 0.42
          },
          "key_drivers": [
            {
              "driver": "Zepbound/Mounjaro demand growth",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Manufacturing capacity expansion",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Obesity net pricing pressure",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Oral incretin pipeline readouts",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "International obesity launches",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Policy and reimbursement scrutiny",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Gross-to-net mix shift",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Core portfolio durability",
              "impact": "LOW",
              "direction": "POS"
            }
          ],
          "method_notes": "Weighted scenario valuation anchored to snapshot fundamentals, forward-growth expectations, and premium pharma multiple discipline; no sell-side price targets used. Snapshot quote fields were kept authoritative. HOLD fits ~4% 12M upside versus current price with meaningful policy, supply, and valuation risk; not investment advice.",
          "current_price": 953.3,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Obesity franchise still drives outsized revenue and EPS growth.",
            "Forward P/E near 31x already discounts substantial execution success.",
            "Supply additions support volumes, but pricing pressure may intensify.",
            "Pipeline optionality, especially oral incretins, underpins premium valuation.",
            "Risk-reward looks balanced after sharp rerating; limited 12M upside."
          ],
          "target_price_6m": 1008,
          "target_price_12m": 990
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "openai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "resp_0cc0639dc7afd6a70069d75ad402588193a162f388535b5f92",
            "reasoningEffort": "medium",
            "structuredOutputs": {
              "used": true,
              "requested": true,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 35762,
        "createdAt": "2026-04-09T05:21:18.826Z",
        "usage": {
          "inputTokens": 2368,
          "outputTokens": 2063,
          "costUsd": 0.033026
        }
      },
      {
        "id": "cmnr14gz404tup6582rn2d7ra",
        "runId": "cmnr14gz104tqp6588uvwhpkl",
        "modelId": "xai.grok-4.20-reasoning",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"Hybrid DCF Model\",\n  \"as_of\": \"2026-04-08T20:03:03.000Z\",\n  \"ticker\": \"LLY\",\n  \"currency\": \"USD\",\n  \"current_price\": 953.3,\n  \"target_price_6m\": 1020,\n  \"target_price_12m\": 1100,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.62,\n  \"thesis_bullets\": [\n    \"Robust demand for tirzepatide sustains revenue growth\",\n    \"Pipeline progress in Alzheimer's and heart failure\",\n    \"Operating leverage drives margin improvement\",\n    \"Intense competition from peers limits pricing power\",\n    \"Premium valuation needs consistent execution\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"GLP-1 market expansion\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Pipeline approvals\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Margin expansion\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Competitive intensity\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Regulatory developments\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Manufacturing capacity\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Pricing pressure\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Patent cliffs\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    }\n  ],\n  \"risks\": [\n    \"Competition eroding market share\",\n    \"Clinical or regulatory setbacks\",\n    \"Supply chain constraints\",\n    \"Multiple contraction at high valuation\",\n    \"Legal risks from side effects\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.22,\n    \"ebit_margin_target\": 0.38,\n    \"wacc\": 0.085,\n    \"terminal_multiple\": 26\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 780,\n      \"prob\": 0.3,\n      \"notes\": \"Competition and delays pressure growth.\"\n    },\n    \"base\": {\n      \"target_price\": 1100,\n      \"prob\": 0.5,\n      \"notes\": \"Steady demand for core obesity drugs.\"\n    },\n    \"bull\": {\n      \"target_price\": 1380,\n      \"prob\": 0.2,\n      \"notes\": \"Accelerated pipeline wins expand TAM.\"\n    }\n  },\n  \"method_notes\": \"3y DCF with revenue CAGR, EBIT margin, WACC and terminal multiple anchors. 12M target implies 15% upside matching BUY rubric. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:03:03.000Z",
          "model": "Hybrid DCF Model",
          "risks": [
            "Competition eroding market share",
            "Clinical or regulatory setbacks",
            "Supply chain constraints",
            "Multiple contraction at high valuation",
            "Legal risks from side effects"
          ],
          "ticker": "LLY",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Steady demand for core obesity drugs.",
              "target_price": 1100
            },
            "bear": {
              "prob": 0.3,
              "notes": "Competition and delays pressure growth.",
              "target_price": 780
            },
            "bull": {
              "prob": 0.2,
              "notes": "Accelerated pipeline wins expand TAM.",
              "target_price": 1380
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.22,
            "terminal_multiple": 26,
            "ebit_margin_target": 0.38
          },
          "key_drivers": [
            {
              "driver": "GLP-1 market expansion",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Pipeline approvals",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Margin expansion",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Competitive intensity",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Regulatory developments",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Manufacturing capacity",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Pricing pressure",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Patent cliffs",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "3y DCF with revenue CAGR, EBIT margin, WACC and terminal multiple anchors. 12M target implies 15% upside matching BUY rubric. Not investment advice.",
          "current_price": 953.3,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Robust demand for tirzepatide sustains revenue growth",
            "Pipeline progress in Alzheimer's and heart failure",
            "Operating leverage drives margin improvement",
            "Intense competition from peers limits pricing power",
            "Premium valuation needs consistent execution"
          ],
          "target_price_6m": 1020,
          "target_price_12m": 1100
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "xai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "8c6b1a81-cc7f-9b7b-bb1e-56067450ac00",
            "usedFallbackChatCompletions": false
          },
          "sanityIssues": []
        },
        "latencyMs": 19670,
        "createdAt": "2026-04-09T05:21:18.826Z",
        "usage": {
          "inputTokens": 2707,
          "outputTokens": 3367,
          "costUsd": 0.058626
        }
      }
    ]
  }
}